LY2510924

DRUG4 trials

Sponsors

Eli Lilly and Company, M.D. Anderson Cancer Center

Conditions

Extensive Stage Small Cell Lung CarcinomaLeukemiaMetastatic Clear Cell Renal Cell CarcinomaSolid Tumor

Phase 1

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

CompletedNCT02652871

M.D. Anderson Cancer CenterLeukemia

Start: 2016-05-09End: 2019-07-16Target: 36Updated: 2019-11-15

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

TerminatedNCT02737072

Eli Lilly and CompanySolid Tumor

Start: 2016-09-30End: 2017-09-25Updated: 2019-08-12

Phase 2

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

TerminatedNCT01391130

Eli Lilly and CompanyMetastatic Clear Cell Renal Cell Carcinoma

Start: 2011-08-31End: 2017-02-28Updated: 2019-07-23

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

CompletedNCT01439568

Eli Lilly and CompanyExtensive Stage Small Cell Lung Carcinoma

Start: 2011-09-30End: 2016-08-31Updated: 2019-07-23

Related Papers

Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML.

Journal of Clinical Oncology2018-05-201 citations

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).

2016-10-0152 citations

Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.

Journal of Clinical Oncology2015-05-207 citations

Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC).

Journal of Clinical Oncology2015-05-203 citations

CXCR4 expression and circulating tumor cell (CTC) counts evaluated as prognostic markers in extensive disease small cell lung cancer (ED-SCLC) patients (pts).

Journal of Clinical Oncology2015-05-201 citations